News

Nov 12, 2021

News Release from Shanghai Zhimeng Biopharma, Inc

Nov 08, 2021

Zhimeng Biopharma announces the closing of $55 million series B financing

Oct 09, 2021

Shanghai Zhimeng Biopharma, Inc. announces the completion of phase 1a clinical study on its novel HBV capsid inhibitor ZM-H1505R and the presentation of the results in the upcoming 2021 annual meeting of the America Association for the Study of Liver Diseases (AASLD) held in November 12-15, 2021

Jun 28, 2021

Shanghai Zhimeng Biopharma appointed Ming Ren as Chief Medical Officer

Jun 09, 2021

Shanghai Zhimeng Biopharma's statement on its scientific advisors

Apr 18, 2021

Zhimeng Biopharma enlisted in Top 100 Biotech Companies in China

Nov 06, 2020

Zhimeng Biopharma Announced Completion of Series A Financing Led by Trinity Innovation Fund (TIF)

Mar 05, 2020

Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R Designed for the Treatment of Chronic Hepatitis B Virus Infection

Jan 19, 2020

Zhimeng Biopharma Received Approval from US FDA for Starting Clinical Trial on Its HBV Capsid Inhibitor ZM-H1505R

Nov 13, 2019

Zhimeng Biopharma Announced Completion of Series Pre-A Financing Led by Lake Capital and Shenzhen Capital Group Co., Ltd.

prev
1
2
3
next

Get in touch

Contact Us About Us Leadership Team Scientific Advisors